Prevention & care
Genital herpes: HSV types, hidden transmission, test limits, recurrence, and antiviral suppression
On this page
Genital herpes is an infection caused by herpes simplex virus type 1 or type 2. HSV-1 can affect the mouth or genitals, while HSV-2 mainly causes genital infection. The virus can remain in the body and reactivate. Many infections are unrecognized; visible sores are not required at every moment for transmission.[1][2]
Type, episode and treatment purpose are different
| Term | Distinction |
|---|---|
| HSV-1 versus HSV-2 | Either can cause genital infection; recurrence patterns can differ.[3] |
| Episodic treatment | Treats a recognized symptomatic episode.[1] |
| Suppressive treatment | Ongoing therapy to reduce recurrences and some transmission risk.[1] |
No current sores does not establish no possible exposure
CDC explains that HSV can spread during contact with genital or oral skin, including when a person does not notice an outbreak. Condoms reduce risk but do not cover every potentially infectious area. Avoiding sexual contact during symptoms and using appropriate prevention are complementary measures, rather than guarantees of zero risk.[2]
Swabs and antibodies answer different questions
CDC describes NAAT or culture from a lesion when present. Antibody testing has timing and false-positive limitations; some low-positive HSV-2 assay results need a second method before interpretation. HSV-1 antibodies do not identify whether infection is oral or genital, and HSV IgM testing is not recommended in this framework.[3]
Population screening differs from investigating symptoms
The 2023 USPSTF statement recommends against routine serologic screening of asymptomatic adolescents and adults, including pregnant people. False-positive results and uncertain benefit can produce net harm. This applies to routine screening, not every person presenting with suggestive symptoms, a relevant history or a separate immunosuppression context.[5]
A diagnosis cannot identify the source partner
NHS explains that symptoms may first become noticeable months or years after infection. Testing cannot determine precisely how long a person has had herpes or who transmitted it. A new recognized outbreak is therefore not proof of a recent exposure or infidelity. Counseling should explain these limits without stigma or blame.[4]
Different goals require different treatment decisions
WHO describes antivirals for episodes and ongoing suppression. Reducing symptoms, reducing recurrence and reducing transmission are separate outcomes, and none means a complete cure. The HSV type, frequency of symptoms, pregnancy, other medicines and personal priorities belong in clinical assessment rather than a universal online drug schedule.[1]
Pregnancy and newborn concerns need their own pathway
Genital HSV can matter during pregnancy and birth. USPSTF distinguishes neonatal-transmission prevention from screening all asymptomatic people. A pregnant person with new symptoms or a relevant history should discuss it with the maternity team; this page does not determine delivery planning or prescribe medication.[5]
Evidence & uncertainty
Antivirals can shorten episodes, reduce recurrences and lower transmission risk, but they do not eradicate HSV. Testing a lesion differs from screening someone without symptoms. A first recognized outbreak does not date acquisition, and a low-positive antibody result can need confirmation. Individual care depends on the clinical context.[3][4]
Selected-source overview · Independent review pendingPublished questions
Can HSV1 cause genital herpes as well as cold sores?
Selected-source overview · Independent review pending. Read the evidence context.
HSV-1 can infect oral or genital sites.[1]
Evidence behind this answer
- Herpes simplex virus
agency condition or prevention explanation · 2025
Selected relevant original official page passages inspected · Virus types, latency, recurrence and treatment purposes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does having no visible herpes sore eliminate transmission risk?
Selected-source overview · Independent review pending. Read the evidence context.
Asymptomatic or unrecognized viral shedding can allow transmission.[2]
Evidence behind this answer
- About Genital Herpes
agency condition or prevention explanation · 2024
Selected relevant original official page passages inspected · Silent infection, oral/genital exposure and partial prevention
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does suppressive herpes treatment eradicate HSV?
Selected-source overview · Independent review pending. Read the evidence context.
It reduces episodes and some transmission risk without curing infection.[1]
Evidence behind this answer
- Herpes simplex virus
agency condition or prevention explanation · 2025
Selected relevant original official page passages inspected · Virus types, latency, recurrence and treatment purposes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a low-positive HSV2 blood test always establish definite infection?
Selected-source overview · Independent review pending. Read the evidence context.
Some low-positive results can be false and need confirmation.[3]
Evidence behind this answer
- Genital Herpes: STI Treatment Guidelines
agency condition or prevention explanation · 2021
Selected relevant original official page passages inspected · Lesion testing, type-specific serology, low positives and IgM limits
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the USPSTF advise routine herpes blood screening for all asymptomatic adults?
Selected-source overview · Independent review pending. Read the evidence context.
Its 2023 statement recommends against routine serologic screening in that population.[5]
Evidence behind this answer
- Genital Herpes Infection: Serologic Screening
agency preventive recommendation · 2023
Selected original recommendation passages inspected · Asymptomatic screening scope, false positives and excluded diagnostic contexts
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a first herpes outbreak establish recent infection or infidelity?
Selected-source overview · Independent review pending. Read the evidence context.
First recognized symptoms may appear long after acquisition and do not identify the source.[4]
Evidence behind this answer
- Genital herpes
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Delayed first recognition, swab purpose and acquisition-date limits
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the valacyclovir transmission trial eliminate all symptomatic HSV2 cases?
Selected-source overview · Independent review pending. Read the evidence context.
It reduced the measured outcome; some infections still occurred.[6]
Evidence behind this answer
- Once-daily valacyclovir to reduce the risk of transmission of genital herpes
randomized trial · 2004
Original indexed abstract and selected original result passages inspected; no independent full-text appraisal · 1484 couples, symptomatic events and partial transmission reduction
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Do HSV1 antibodies identify whether infection is oral or genital?
Selected-source overview · Independent review pending. Read the evidence context.
An antibody result alone does not locate an HSV-1 infection.[3]
Evidence behind this answer
- Genital Herpes: STI Treatment Guidelines
agency condition or prevention explanation · 2021
Selected relevant original official page passages inspected · Lesion testing, type-specific serology, low positives and IgM limits
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
A transmission trial showed reduction rather than elimination
A 2004 randomized trial followed 1,484 immunocompetent heterosexual monogamous couples with differing HSV-2 status. Symptomatic infection developed in 4 of 743 susceptible partners in the valacyclovir group versus 16 of 741 with placebo. The studied endpoint was symptomatic HSV-2, not proof of no infections or a cure in the partner with established infection.[6]
The trial supports a defined suppression strategy in that population and follow-up, rather than an identical risk reduction for every relationship, HSV type or exposure. Some symptomatic infections still occurred. Counseling, baseline risk and other prevention measures matter when translating a relative-effect headline into an individual expectation.[6]
References
- Herpes simplex virus
Agency condition or prevention explanation
World Health Organization · Content/publication date: 2025
Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
Cited sections: Virus types, latency, recurrence and treatment purposesDated 30 May 2025; no personal prevention guarantee.
- About Genital Herpes
Agency condition or prevention explanation
CDC · Content/publication date: 2024
Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
Cited sections: Silent infection, oral/genital exposure and partial preventionDated 20 February 2024.
- Genital Herpes: STI Treatment Guidelines
Agency condition or prevention explanation
CDC · Content/publication date: 2021
Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
Cited sections: Lesion testing, type-specific serology, low positives and IgM limits2021 clinical framework, not a newly issued 2026 protocol.
- Genital herpes
Agency condition or prevention explanation
NHS · Content/publication date: not stated
Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
Cited sections: Delayed first recognition, swab purpose and acquisition-date limitsNo personal source-partner inference.
- Genital Herpes Infection: Serologic Screening
Agency preventive recommendation
US Preventive Services Task Force · Content/publication date: 2023
Accessed: 2026-10-08 UTC · Selected original recommendation passages inspected
Cited sections: Asymptomatic screening scope, false positives and excluded diagnostic contexts14 February 2023 final statement; population-specific recommendation.
- Once-daily valacyclovir to reduce the risk of transmission of genital herpes
Randomized trial
Corey L and colleagues · Content/publication date: 2004
Accessed: 2026-10-08 UTC · Original indexed abstract and selected original result passages inspected; no independent full-text appraisal
Cited sections: 1484 couples, symptomatic events and partial transmission reductionGlaxoSmithKline/NIH-supported; original indexed findings, not full appraisal.
Scope & review
- Population
- General HSV literacy; symptomatic care, asymptomatic screening and a defined couple trial
- Exposure or intervention
- Lesion/antibody testing, episodic/suppressive antivirals and prevention
- Comparison
- Source-specific test methods, placebo/usual care, or prevention settings
- Outcomes
- Symptoms, recurrence, test interpretation, transmission and neonatal concerns
- Timeframe
- Latency, repeated episodes and source-specific trial follow-up
- Jurisdiction
- WHO global frameworks with selected US/UK explanations; eligibility and programs vary locally
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-08 UTC: Added a sourced explanation in a bounded ten-article batch; qualified review remains pending.
What this article still leaves open
- Updated full prevention/treatment comparisons, precise trial follow-up appraisal and pregnancy protocols remain incomplete.
- No individual antibody interpretation, source-partner determination or medication/delivery plan is supplied.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.